美他米唑与布洛芬用于子痫前期重度剖宫产术后镇痛的四盲随机试验
两组术后疼痛分布及血压轨迹无显著差异,美他米唑组急性肾损伤数值上更多但估计极不精确,尚不能确定肾脏安全性差异。
要点
- 美他米唑与布洛芬在剖宫产术后疼痛分布及血压轨迹上无显著差异。
- 美他米唑组急性肾损伤数值更高(7.9% vs 2.8%),但置信区间极宽。
- 该试验非等效或非劣效设计,肾脏安全性比较需足够把握度的研究。
核心结论
- 美他米唑与布洛芬在子痫前期重度剖宫产术后疼痛及血压轨迹上未见明确组间差异。
- 美他米唑组急性肾损伤数值上更频繁,但估计高度不精确,比较性肾脏安全性仍不确定。
研究设计与样本
- 四盲(受试者、照护者、研究者、结局评估者)、随机、活性对照、4 期试验,在巴西东北部一家三级妇产医院开展。
主要发现
- 第 1 天注册的三分类疼痛分布组间无差异(精确 P=.45),第 2 天亦无差异(精确 P=.55)。
- 第 1 天两组 VAS 中位数均为 4(IQR 2-5),第 2 天美他米唑组 IQR 2-4、布洛芬组 3(IQR 2-4)。
- 第 1 至第 2 天 VAS 平均下降美他米唑组 1.0(SD 2.1)对比布洛芬组 0.6(SD 2.4),组间下降差值 0.36 分(95% CI -0.70 至 1.42;P=.50)。
- 第 1 天补救镇痛比例美他米唑组 18.4% 对比布洛芬组 38.9%(风险差 -20.5 个百分点,95% CI -39.1 至 0.1)。
- 急性肾损伤美他米唑组 3/38(7.9%)对比布洛芬组 1/36(2.8%)(风险比 2.84;95% CI 0.31-26.08;Fisher P=.62;风险差 +5.1 个百分点,95% CI -7.4 至 18.2)。
临床怎么用
- 对于子痫前期重度剖宫产术后产妇,美他米唑与布洛芬在疼痛控制和血压方面未显示明确差异。
- 选择美他米唑时需关注急性肾损伤的数值信号,但现有证据不足以确定肾脏安全性差异。
局限性
- 该试验未设计为等效或非劣效研究。
- 急性肾损伤估计高度不精确,比较性肾脏安全性需足够把握度的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adequate analgesia after cesarean delivery is a priority in women with preeclampsia, in whom opioid-sparing strategies are desirable. Nonsteroidal anti-inflammatory drugs (NSAIDs) were historically avoided in hypertensive disorders of pregnancy because of a presumed effect on blood pressure, but randomized trials and meta-analyses have since shown no clinically meaningful blood-pressure effect, and current guidance supports their postpartum use when otherwise appropriate. Metamizole (dipyrone) is a non-opioid analgesic widely used in Brazil, Latin America, and parts of Europe, but its regulatory status varies internationally. It is not approved in the United States, and agranulocytosis is a recognized rare but potentially serious adverse reaction. European regulatory guidance also advises against its use during breastfeeding. No randomized trial has directly compared metamizole with an NSAID after cesarean delivery in women with preeclampsia. OBJECTIVE: To compare metamizole and ibuprofen for analgesic effectiveness and short-term safety, with particular attention to blood pressure trajectory and renal function, after cesarean delivery in women with preeclampsia with severe features. STUDY DESIGN: Quadruple-blind (participant, care provider, investigator, outcome assessor), randomized, active-comparator, phase 4 trial at a tertiary maternity hospital in northeastern Brazil. Seventy-four women received oral metamizole 1 g or ibuprofen 400 mg every 6 hours for up to 5 days, with intravenous tramadol available as rescue analgesia. Co-primary outcomes, as prospectively registered, were postoperative pain-categorized as mild, moderate, or severe by visual analogue scale (VAS)-and acute kidney injury (AKI). Continuous VAS, the D1-to-D2 mean reduction in VAS, the clinically interpretable threshold VAS ≥4, the Faces Pain Scale-Revised, peri-incisional pressure pain thresholds by algometry, rescue analgesia, serial blood pressure, hypertensive episodes, laboratory values, satisfaction, and length of stay were secondary or supportive outcomes. Effects were estimated with risk differences, risk ratios, exact tests, Hodges-Lehmann differences, standardized effect sizes with Holm correction, and linear mixed-effects models. RESULTS: Thirty-eight women were allocated to metamizole and 36 to ibuprofen. The registered three-category pain distribution did not differ between groups on day 1 (exact P=.45) or day 2 (exact P=.55). Median VAS was 4 (IQR 2-5) in both groups on day 1 and 2 (IQR 2-4) versus 3 (IQR 2-4) on day 2; the mean D1-to-D2 VAS reduction was 1.0 (SD 2.1) versus 0.6 (SD 2.4), with a mean between-group difference in reduction of 0.36 points (95% CI -0.70 to 1.42; P=.50). Rescue analgesia on day 1 was required by 18.4% versus 38.9% (risk difference -20.5 percentage points, 95% CI -39.1 to 0.1). AKI occurred in 3 of 38 (7.9%) versus 1 of 36 (2.8%) (risk ratio 2.84; 95% CI 0.31-26.08; Fisher P=.62; risk difference +5.1 percentage points, 95% CI -7.4 to 18.2). Linear mixed-effects models showed no group-by-time interaction for systolic (P=.14) or diastolic (P=.18) blood pressure; robust GEE sensitivity analyses were concordant. Severe hypertensive episodes were rare in both arms. CONCLUSION: In this randomized trial, no clear between-group difference was detected in postoperative pain or blood-pressure trajectory. The trial was not designed as an equivalence or non-inferiority study. AKI was numerically more frequent with metamizole, but the estimate was highly imprecise; comparative renal safety remains uncertain and requires adequately powered studies.
引用
- Pordeus ACB, Katz L, Maia MT, et al. Metamizole (dipyrone) versus ibuprofen for post-cesarean analgesia in women with preeclampsia with severe features: a quadruple-blind, randomized, active-comparator trial. Am J Obstet Gynecol MFM. 2026. PMID: 42966477. doi:10.1016/j.ajogmf.2026.102162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。